Back to Agenda
IBM Innovation Theater: New Ways to Apply Decentralized Trials During Covid-19
Session Chair(s)
Robert DiCicco, PharmD
Vice President, Portfolio Management
TransCelerate Biopharma Inc., United States
The industry is facing an even bigger challenge to recruit, retain, and engage with patients due to COVID-19. This has delayed and de-prioritized many clinical trials across the globe. In response, IBM Watson Health has optimized IBM Clinical Development to enable decentralized trials for its clients, specifically leveraging its eCOA capabilities and its unified, cloud-based CDMS platform that allows remote monitoring and study control. Biorasi will be speaking as a user of this platform on how ICD is helping them overcome COVID-19-related challenges and how to help their Sponsors operate more efficiently.
Speaker(s)
Panelist
Sébastien Bohn
IBM Watson Health, France
Offering Manager Executive
Have an account?